Aberrant expression of five miRNAs in papillary thyroid carcinomas

• Published in: Journal of clinical laboratory analysis Vol. 35; no. 9; pp. e23907 - n/a
• Main Authors: Qiao, De‐hui, He, Xue‐mei, Deng, Xian, Ji, Yi‐chi, Yang, Hui, Cheng, Lian, Zhou, Xiang‐yu
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.09.2021; John Wiley and Sons Inc
• Subjects: Biomarkers, Tumor - genetics; clinicopathological features; diagnosis; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymph nodes; Lymphatic system; Male; Metastases; Metastasis; MicroRNAs; MicroRNAs - genetics; Middle Aged; miRNA; molecular marker; Papillary thyroid carcinoma; Prognosis; ROC Curve; Thyroid; Thyroid cancer; Thyroid Cancer, Papillary - genetics; Thyroid Cancer, Papillary - pathology; Thyroid Cancer, Papillary - surgery; Thyroid Neoplasms - genetics; Thyroid Neoplasms - pathology; Thyroid Neoplasms - surgery; Tumors; Variance analysis; clinicopathological features; diagnosis; miRNA; papillary thyroid carcinoma; molecular marker
• ISSN: 0887-8013; 1098-2825
• DOI: 10.1002/jcla.23907

Background The miRNAs play critical roles in the progression of various tumors. Our study aimed to screen and identify miRNAs to investigate their diagnostic and prognostic value for papillary thyroid carcinoma (PTC). Methods miRNAs were evaluated in PTC (n = 30) tissues, A‐PTC (n = 30), benign nodules (n = 35) and A‐benign nodules (n = 35). The expression levels of five miRNAs were quantified using real‐time, quantitative PCR. ROC analysis was used to evaluate the miRNA diagnostic value. Results The expression of miR‐1296‐5p, miR‐1301‐3p, and miR‐532‐5p was significantly downregulated (p = 0.0001, p = 0.0006, p = 0.0024, respectively), while miR‐551b‐3p and miR‐455‐3p were significantly upregulated in PTC tissues compared to A‐PTC tissues (p = 0.0005, p = 0.0046, respectively). Interestingly, the expression of miR‐1296‐5p was downregulated, while miR‐551b‐3p and miR‐455‐3p were upregulated in the A‐PTC group compared to the A‐benign group. Moreover, the miR‐1296‐5p expression level was associated with tumor size, the number of foci and the TNM stage; the miR‐455‐3p expression level was correlated with patient age, tumor size, and TNM stage; and the miR‐532‐5p expression level was correlated with patient age, lymph node metastasis and TNM stage correspondingly. ROC analysis revealed that the AUCs for miR‐1301‐3p, miR‐1296‐5p, miR‐455‐3p, miR‐532‐5p, and miR‐551b‐3p were 0.773, 0.790, 0.783, 0.744, and 0.650, respectively. Conclusions Our results indicated that miR‐1296‐5p, miR‐1301‐3p, miR‐532‐5p, miR‐551b‐3p, and miR‐455‐3p are aberrantly expressed in papillary thyroid carcinomas and correlated with clinicopathological features. ROC curve analysis indicated that these five miRNAs have a potential diagnostic value. Consequently, we speculate that the five altered miRNAs may serve as potential diagnostic and prognostic biomarkers for PTC. miR‐1296‐5p, miR‐1301‐3p and miR‐532‐5p were significantly downregulated (p = 0.0001, p = 0.0006, p = 0.0024, respectively), while miR‐551b‐3p and miR‐455‐3p were significantly upregulated in PTC tissues compared to A‐PTC (p = 0.0005, p = 0.0046, respectively). Aberrant expression of miR‐1296‐5p, miR‐532‐5p, and miR‐455‐3p are correlation with clinical‐pathological features. ROC cure indicated that those five miRNAs have diagnostic value.